Skip to content

Votioxetine in the treatment of IBS

Votioxetine in the treatment of IBS: a randomized, placebo controlled trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20090117001556N105
Enrollment
50
Registered
2017-12-25
Start date
2018-01-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

En Irritable bowel syndrome. Irritable bowel syndrome

Interventions

Intervention 1: Intervention group: Capsule Vortioxetine 10mg/day as intervention group for 6 weeks. Intervention 2: Control group: receiving placebo for 6 weeks.
Treatment - Drugs
Placebo
Intervention group: Capsule Vortioxetine 10mg/day as intervention group for 6 weeks
Control group: receiving placebo for 6 weeks

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: age 18-65 years old IBS diagnosis through ROME IV criteria moderate to severe symptoms through severity of symptom

Exclusion criteria

Exclusion criteria: diagnosis of any organic disease related to symptoms any psychiatric disorder pregnancy taking any other psychotropic drugs during 4 weeks before entering to the trial breastfeeding

Design outcomes

Primary

MeasureTime frame
Severity of symptom. Timepoint: Baseline and weeks 2-4-6 after beginig of treatment. Method of measurement: IBS-SSS questionnaire.

Secondary

MeasureTime frame
Quality of life. Timepoint: Baseline and weeks 2-4-6 after beginig of treatment. Method of measurement: IBS QOL.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026